Team
Apeiron’s leadership team, based in the San Francisco Bay Area and Shanghai.
-
Mingxi Li, PhD
Co-founder and Chief Executive Officer
An investor and entrepreneur focused on early-stage life science innovation and cross-border company building. Mingxi is a partner at GT Healthcare Capital Partners. He began his career in healthcare investing at Jiuding Capital, then worked on global early-stage pharmaceutical investments at Simcere Pharmaceutical Group. He graduated from Tsinghua University and holds a PhD in biochemistry from the University of Illinois at Urbana-Champaign.
-
Fred Aswad, JD, PhD
Co-founder and Chief Scientific Officer
Fred has more than 20 years of biotechnology research and development experience. At Bayer he led development of the immuno-oncology portfolio and built new drug discovery platforms. As Senior Director of Biology at IDEAYA Biosciences, he advanced targeted small molecules combining immuno-oncology and synthetic lethality. He holds a PhD in immunology from the University of Southern California and a JD from Santa Clara University School of Law, specializing in intellectual property.
-
Xiaohui Gu, PhD
Senior Vice President, Chemistry
Xiaohui has more than 20 years of pharmaceutical research and development experience across X-Ceptor, Exelixis, ShangPharma, Otsuka and Pharmaron, and was Senior Director of R&D at Simcere Pharmaceutical Group before joining Apeiron. He earned his doctorate in organic chemistry at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, with postdoctoral training at the NIH under Kenner C. Rice and at McLean Hospital, Harvard Medical School, under John L. Neumeyer.
-
Jim Joseph, PhD
Vice President, Biology
Jim has more than 15 years of small molecule oncology discovery experience, from target identification and validation through translational biology for clinical trials. He led new target identification at IDEAYA Biosciences as an Associate Director. Before that he directed in vitro biology for the androgen receptor program (Erleada®) at Aragon and the estrogen receptor antagonist program at Seragon. He holds a PhD in pharmacology from Duke University and is an author on more than 25 publications and patents.
-
Ling Zeng
Senior Director, Clinical Operations
Ling has nearly 15 years of project and team management experience in clinical trials, including global and local Phase 1–3 studies, mainly in oncology. She previously held project and team management roles at R&G, IQVIA, MSD and Forward Pharmaceutical. She holds a master’s degree in clinical medicine and is pursuing further study in public health at Peking University.
-
Yanfeng Zhou
Senior Director, CMC
Yanfeng has more than 15 years of experience in drug discovery and non-clinical development, focused on CMC. As R&D director at 2Y-Chem, he led several programs through non-clinical development and into Phase 1, and he has supported several IND and ANDA applications. He holds a master’s degree in pharmaceutical chemistry from China Pharmaceutical University.
-
Minghua Wang, PhD
Director, Artificial Intelligence Guided Drug Discovery
Minghua has more than 15 years of small molecule discovery experience, applying computational chemistry to targets from enzymes to receptors. Most recently he worked on membrane protein targets in neuroscience at Cerevel Therapeutics. He holds a PhD from the Chinese Academy of Sciences and is an author on more than 25 patents and publications.
-
Qin Wang, PhD
Director, Biology
Qin has more than nine years of discovery and development experience in in vitro biology, from target identification and validation to translational work supporting clinical trials. At BeOne he supported or led more than ten projects across small molecules, PROTACs, monoclonal antibodies, bispecific antibodies and ADCs. He holds a PhD from the Institute of Biophysics, Chinese Academy of Sciences.
-
Bing Yao, PhD
Director, Chemistry
Bing has more than five years of drug development experience in targeted anti-cancer therapeutics and central nervous system drugs, at the Shanghai Institute of Organic Chemistry and Shenzhen Phytovent Biopharma. He led the chemistry that brought the BTK inhibitor MH048 and the mitochondria-targeting candidate QB0208-1 into clinical development. He earned his PhD in chemical biology from the Shanghai Institute of Organic Chemistry in 2018.
Careers
For information about open positions, contact inquiries@apeiron-bio.us.